A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
ClinicalTrials.gov ID
NCT01231334
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
286Actual
Last Update Posted
Jul 27, 2012Estimated
Start Date
Aug 2010
Primary Completion Date
Jun 2011Actual
Completion Date
Jun 2011Actual
Brief Summary
A study comparing the topical application of Aczone® plus Differin® versus Duac® plus Differin® in patients with severe facial acne (facial acne vulgaris).
Acne Vulgaris
Dapsone plus Adapalene
Clindamycin/benzoyl peroxide plus Adapalene
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Severe facial acne (acne vulgaris)
Exclusion Criteria:
History of significant anemia or hemolysis
History of enteritis (eg, regional enteritis, ulcerative colitis, pseudomembranous colitis, antibiotic-associated colitis)
History of lupus, rosacea, or seborrheic dermatitis